This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Top 10 'Buy'-Rated Stocks Under $5

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

9. Corcept Therapeutics (CORT)

Company Profile: Corcept Therapeutics is a biopharmaceutical company developing Corlux, a synthetic steroid to treat Cushing's syndrome.

Share Price: $4.22 (March 29)

Stock Performance This Year: 9%

Analyst Consensus: Seven Wall Street firms rate Corcept a "buy," including Stifel Nicolaus and Piper Jaffray. Only one analyst says investors should dump shares. The average price target of $6.60 implies potential upside of 56%.

Bullish Case: McNicoll Lewis Vlak analyst Christopher James initiated coverage of Corcept on March 10 with a "buy" rating and $8.50 price target. "Given the interviews conducted with both endocrinologists and practicing neurosurgeons, we feel uniquely positioned in the understanding of Cushing's syndrome, and the approvability and potential market size for Corlux," James wrote in his research note, adding that he has a high level of confidence that Corlux will be approved in early 2012.

TheStreet Ratings doesn't have a rating on Corcept Therapeutics.
3 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
C $55.37 0.00%
CIM $13.93 0.00%
DRYS $0.59 0.00%
GST $2.85 0.00%
S $4.48 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs